Table 2.
Changes in urinary osmolality, NT-proBNP, and copeptin during dapagliflozin therapy versus placebo in various subgroups.
| Baseline Subgroups | Mean Baseline Urinary Osmolality (mOsmoL/kg) (SD) | Change in Urinary Osmolality (mOsmoL/kg) (95% CI; p-Value) |
Median Baseline NT-proBNP (ng/L) (IQR) |
Change in NT-proBNP (%) (95% CI; p-Value) |
Median Baseline Copeptin (pmoL/L) (IQR) |
Change in Copeptin (%) (95% CI; p-Value) |
Median Baseline Renin (ng/L) (IQR) |
Change in Renin (%) (95% CI; p-Value) |
|---|---|---|---|---|---|---|---|---|
| Diuretics use Yes (N = 44) No (N = 25) |
554 (168) 573 (196) |
63.1 (24.7, 101.5; p < 0.01) 59.1 (8.2, 110.0; p = 0.02) |
75 (35, 201) 113 (38, 206) |
−3.8% (−22.2, 13.5; p = 0.65) 7.1% (−33.6, 16.4; p = 0.54) |
7.3 (5.4, 11.2) 9.0 (5.9, 10.9) |
29.6% (18.7, 41.6; p < 0.01) 39.1% (23.9, 56.1; p < 0.01) |
38 (19, 85) 29 (17, 72) |
52.6% (20.4, 93.4; p < 0.01) 38.7% (1.6, 89.3; p = 0.04) |
| p for interaction | p = 0.19 | p = 0.39 | p = 0.41 | p = 0.08 | ||||
| HbA1c (mmoL/moL) <63 ≥63 |
532 (175) 589 (177) |
71.7 (27.7, 115.8; p < 0.01) 51.4 (9.0, 93.8; p = 0.02) |
110 (35, 209) 100 (35, 201) |
4.1% (-16.2, 25.8; p=0.68) −13.0% (−35.0, 5.8; p = 0.18) |
7.5 (5.6, 11.2) 9.0 (5.8, 14.0) |
32.0% (19.0, 46.5; p < 0.01) 35.3% (19.0, 53.7; p < 0.01) |
29 (19, 87) 40 (15, 85) |
32.2% (1.07, 73.0; p = 0.04) 62.7% (25.3, 111.2; p < 0.01) |
| p for interaction | p = 0.51 | p = 0.76 | p = 0.49 | p = 0.56 | ||||
| Estimated GFR (mL/min/1.73 m2) <82 ≥82 |
509 (152) 611 (188) |
65.4 (21.2, 109.5; p < 0.01) 57.1 (14.6, 99.6; p < 0.01) |
118 (53, 263) 66 (35, 150) |
−4.8% (−26.1, 14.7; p = 0.61) −4.6% (−26.2, 15.3; p = 0.63) |
9.2 (6.3, 16.4) 7.1 (4.5, 10.0) |
36.7% (23.6, 51.2; p < 0.01) 29.5% (17.4, 42.8; p < 0.01) |
29 (20, 113) 41 (11, 70) |
48.5% (13.3, 94.7; p < 0.01) 46.0% (12.2, 90.0; p = 0.01) |
| p for interaction | p = 0.68 | p = 0.85 | p = b0.46 | p = 0.66 | ||||
| UACR (mg/g) <199.7 ≥199.7 |
591 (199) 532 (151) |
76.8 (33.6, 120.0; p < 0.01) 46.6 (3.7, 89.5; p = 0.03) |
75 (35, 201) 112 (53, 263) |
−10.3% −33.3, 9.5; p = 0.30) −0.1% (−19.8, 20.0; p = 0.99) |
7.7 (5.8, 10.9) 8.9 (5.7, 11.2) |
32.5% (19.9, 46.4; p < 0.01) 33.5% (20.8, 47.5; p < 0.01) |
38 (17, 67) 37 (19, 85) |
45.4% (11.3, 89.8; p < 0.01) 49.0% (14.1, 94.7, p < 0.01) |
| p for interaction | p = 0.92 | p = 0.71 | p = 0.29 | p = 0.41 |
HbA1c, eGFR, and UACR were split by using the median value (merged database).